All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-05-25T13:05:21.000Z

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

By Georgia Scurfield, Maria Kasimati, Zoe Brunn, Camilla Rossi
Featured
Elias Jabbour
May 25, 2021
Share:

Bookmark this article

During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

In this video, Jabbour discusses the impact of targeted therapies for adult patients with ALL, including tyrosine kinase inhibitors, monoclonal and conjugated antibodies, bispecific engagers, and chimeric antigen receptor (CAR) T cells. He believes targeted therapies significantly improve the outcomes of patients with high disease burden.

More about...
AdultCAR therapyConjugated antibodiesESH 2021Tyrosine kinase inhibitors

Related articles

Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell therapy outcomes in pediatric, adolescents, and...

Dec 21, 2023
Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell...

Dec 21, 2023
Add bookmark

When should we consider allo-HSCT in a patient with ALL? And when not?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research...

Feb 17, 2021
Add bookmark

When should we consider allo-HSCT in a patient with ALL? And when not?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel,...

Feb 17, 2021

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox